At La Jolla Institute for Immunology, scientists have made a breakthrough that could reshape how we defend against some of the world's deadliest viral families: a single "pan-arenavirus" vaccine might protect against Lassa virus, Junin virus, and many other arenaviruses in one shot. The discovery, published in Cell Reports Medicine, reveals that the human immune system can recognize a family resemblance among viruses that have diverged for 45,000 years—and that insight could transform pandemic preparedness.
Arenaviruses kill thousands annually and spread the way nightmares do in global health: silently, from rodent to human, with pandemic potential baked into their biology. Lassa virus alone, the deadliest arenavirus, claims between 5,000 and 10,000 lives each year in West African countries, where it spreads via the multimammate rat. Victims suffer severe flu-like symptoms that can progress to bleeding from the mouth or gastrointestinal tract. Eight arenavirus species are known to infect humans, with dozens more circulating in animal populations, making the threat both present and precarious.
What makes this research pivotal is how scientists exploited the immune system's pattern recognition. Professor Alessandro Sette and Research Assistant Professor Alba Grifoni, who co-led the study, discovered that T cells—the body's disease-fighting guardians—can spot shared molecular structures, called epitopes, across different arenavirus species. "T cells are good at recognizing viruses, even if a virus is mutating," Grifoni explains. This "cross-reactivity" is the key. An immune response trained to fight one arenavirus can recognize and attack its distant cousins.
The work began with Old World arenaviruses, the group found in Europe, Africa, and Asia. The scientists identified that human T cells can cross-react to epitopes shared by all Old World arenavirus species—meaning a vaccine against Lassa virus could potentially protect against the Old World Lujo virus and lymphocytic choriomeningitis virus. Experimental Lassa virus vaccines already in development can induce exactly these cross-reactive T cells, pointing toward real clinical applications in the near term.
New World arenaviruses, which evolved separately in the Americas over tens of thousands of years, presented a different puzzle. They've drifted far enough that Old World T cells don't recognize them. But research led by postdoctoral associate YeiI Lee found that T cells can also cross-react within the New World family. Analyzing responses from people in Argentina who had received a Junin virus vaccine—which causes Argentine hemorrhagic fever—the team identified shared epitopes among New World species.
The implications ripple outward. "We can apply this new research approach to multiple viral families, no matter how rare they are in the human population," Grifoni said. This matters because predicting which animal virus will jump to humans and spark an outbreak is nearly impossible. But if scientists can design vaccines that harness cross-reactive T cells, they can build immunity against entire viral families before a crisis hits.
Sette emphasized the work ahead: "We are now moving toward the next steps of designing vaccines and seeing which formulations may work best." The research arrives as scientists race to contain the Andes hantavirus, which recently killed passengers aboard a cruise ship—a reminder that emerging viruses won't wait for perfect preparation. With T cell cross-reactivity as their compass, researchers now have a clearer path to vaccines that protect not against single threats, but against entire families of them.